Skip to main content
Erschienen in: Familial Cancer 4/2011

01.12.2011

Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care center

verfasst von: K. Ready, B. K. Arun, K. M. Schmeler, A. Uyei, J. K. Litton, K. H. Lu, C. C. Sun, S. K. Peterson

Erschienen in: Familial Cancer | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Individuals at high risk for hereditary cancers often receive genetic counseling and testing at tertiary care centers; however, they may receive care for long-term management of their cancer risk in community settings. Communication of genetic test results to health care providers outside of tertiary care settings can facilitate the long-term management of high risk individuals. This study assessed women’s communication of BRCA1/BRCA2 genetic test results to health care providers outside of tertiary care settings (termed “outside” health care providers, or OHCPs) and women’s perceptions regarding communication of results. Women (n = 312) who underwent BRCA1/BRCA2 genetic counseling and testing completed a questionnaire assessing whether or not they shared test results with OHCPs and perceptions regarding the communication of test results to OHCPs. Most (72%) shared genetic test results with OHCPs. Women with no personal history of cancer were more likely to have shared results compared to women with a personal history of cancer. Mutation status did not significantly predict sharing of genetic information. Most reported positive perceptions regarding the disclosure of genetic test results to OHCPs. The majority did not report any concerns about potential insurance discrimination (88%) and indicated that OHCPs were able to appropriately address their questions (81%). Although most women shared their genetic test results with OHCPs, those with a personal history of cancer may need further encouragement to share this information. Tertiary care centers should facilitate outreach and education with OHCPs in order to assure appropriate long-term cancer risk management for high risk populations.
Literatur
1.
Zurück zum Zitat Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329–1333PubMedCrossRef Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329–1333PubMedCrossRef
2.
Zurück zum Zitat Ford D, Easton DF, Bishop DT et al (1994) Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet 343:692–695PubMedCrossRef Ford D, Easton DF, Bishop DT et al (1994) Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet 343:692–695PubMedCrossRef
3.
Zurück zum Zitat Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62:676–689PubMedCrossRef Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62:676–689PubMedCrossRef
4.
Zurück zum Zitat Saslow D, Boetes C, Burke W et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75–89PubMedCrossRef Saslow D, Boetes C, Burke W et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75–89PubMedCrossRef
5.
Zurück zum Zitat King MC, Wieand S, Hale K et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) breast cancer prevention trial. JAMA 286:2251–2256PubMedCrossRef King MC, Wieand S, Hale K et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) breast cancer prevention trial. JAMA 286:2251–2256PubMedCrossRef
6.
Zurück zum Zitat Narod SA, Brunet JS, Ghadirian P et al (2000) Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356:1876–1881PubMedCrossRef Narod SA, Brunet JS, Ghadirian P et al (2000) Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356:1876–1881PubMedCrossRef
7.
Zurück zum Zitat Antoniou AC, Rookus M, Andrieu N et al (2009) Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 18:601–610PubMedCrossRef Antoniou AC, Rookus M, Andrieu N et al (2009) Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 18:601–610PubMedCrossRef
8.
Zurück zum Zitat McLaughlin JR, Risch HA, Lubinski J et al (2007) Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 8:26–34PubMedCrossRef McLaughlin JR, Risch HA, Lubinski J et al (2007) Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 8:26–34PubMedCrossRef
9.
Zurück zum Zitat Hartmann LC, Sellers TA, Schaid DJ et al (2001) Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93:1633–1637PubMedCrossRef Hartmann LC, Sellers TA, Schaid DJ et al (2001) Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93:1633–1637PubMedCrossRef
10.
Zurück zum Zitat Meijers-Heijboer H, van Geel B, van Putten WL et al (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159–164PubMedCrossRef Meijers-Heijboer H, van Geel B, van Putten WL et al (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159–164PubMedCrossRef
11.
Zurück zum Zitat Rebbeck TR, Friebel T, Lynch HT et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22:1055–1062PubMedCrossRef Rebbeck TR, Friebel T, Lynch HT et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22:1055–1062PubMedCrossRef
12.
Zurück zum Zitat Kauff ND, Satagopan JM, Robson ME et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609–1615PubMedCrossRef Kauff ND, Satagopan JM, Robson ME et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609–1615PubMedCrossRef
13.
Zurück zum Zitat Rebbeck TR, Levin AM, Eisen A et al (1999) Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91:1475–1479PubMedCrossRef Rebbeck TR, Levin AM, Eisen A et al (1999) Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91:1475–1479PubMedCrossRef
14.
Zurück zum Zitat Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–1622PubMedCrossRef Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–1622PubMedCrossRef
15.
Zurück zum Zitat Olopade OI, Artioli G (2004) Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations. Breast J 10(Suppl 1):5–9CrossRef Olopade OI, Artioli G (2004) Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations. Breast J 10(Suppl 1):5–9CrossRef
16.
Zurück zum Zitat Kurian AW, Sigal BM, Plevritis SK (2009) Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 28:222–231PubMedCrossRef Kurian AW, Sigal BM, Plevritis SK (2009) Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 28:222–231PubMedCrossRef
17.
Zurück zum Zitat McInerney JD (2008) Genetics education for health professionals: a context. J Genet Couns 17:145–151PubMedCrossRef McInerney JD (2008) Genetics education for health professionals: a context. J Genet Couns 17:145–151PubMedCrossRef
18.
Zurück zum Zitat ACOG Practice Bulletin No. 103 (2009) Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 113:957–966 ACOG Practice Bulletin No. 103 (2009) Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 113:957–966
19.
Zurück zum Zitat NCCN Clinical Practice Guidelines. Genetic/Familial High-Risk Assessment: Breast and Ovarian (2009) www.nccn.org. Retrieved 10 Jan 2010 NCCN Clinical Practice Guidelines. Genetic/Familial High-Risk Assessment: Breast and Ovarian (2009) www.​nccn.​org. Retrieved 10 Jan 2010
20.
Zurück zum Zitat Nelson HD, Huffman LH, Fu R et al (2005) Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the US preventive services task force. Ann Intern Med 143:362–379PubMed Nelson HD, Huffman LH, Fu R et al (2005) Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the US preventive services task force. Ann Intern Med 143:362–379PubMed
21.
Zurück zum Zitat Lancaster JM, Powell CB, Kauff ND et al (2007) Society of gynecologic oncologists education committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 107:159–162PubMedCrossRef Lancaster JM, Powell CB, Kauff ND et al (2007) Society of gynecologic oncologists education committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 107:159–162PubMedCrossRef
22.
Zurück zum Zitat Acton RT, Burst NM, Casebeer L et al (2000) Knowledge, attitudes, and behaviors of Alabama’s primary care physicians regarding cancer genetics. Acad Med 75:850–852PubMedCrossRef Acton RT, Burst NM, Casebeer L et al (2000) Knowledge, attitudes, and behaviors of Alabama’s primary care physicians regarding cancer genetics. Acad Med 75:850–852PubMedCrossRef
23.
Zurück zum Zitat Freedman AN, Wideroff L, Olson L et al (2003) US physicians’ attitudes toward genetic testing for cancer susceptibility. Am J Med Genet A 120A:63–71PubMedCrossRef Freedman AN, Wideroff L, Olson L et al (2003) US physicians’ attitudes toward genetic testing for cancer susceptibility. Am J Med Genet A 120A:63–71PubMedCrossRef
24.
Zurück zum Zitat Pichert G, Dietrich D, Moosmann P et al (2003) Swiss primary care physicians’ knowledge, attitudes and perception towards genetic testing for hereditary breast cancer. Fam Cancer 2:153–158PubMedCrossRef Pichert G, Dietrich D, Moosmann P et al (2003) Swiss primary care physicians’ knowledge, attitudes and perception towards genetic testing for hereditary breast cancer. Fam Cancer 2:153–158PubMedCrossRef
25.
Zurück zum Zitat Escher M, Sappino AP (2000) Primary care physicians’ knowledge and attitudes towards genetic testing for breast-ovarian cancer predisposition. Ann Oncol 11:1131–1135PubMedCrossRef Escher M, Sappino AP (2000) Primary care physicians’ knowledge and attitudes towards genetic testing for breast-ovarian cancer predisposition. Ann Oncol 11:1131–1135PubMedCrossRef
26.
Zurück zum Zitat Armstrong K, Stopfer J, Calzone K et al (2002) What does my doctor think? Preferences for knowing the doctor’s opinion among women considering clinical testing for BRCA1/2 mutations. Genet Test 6:115–118PubMedCrossRef Armstrong K, Stopfer J, Calzone K et al (2002) What does my doctor think? Preferences for knowing the doctor’s opinion among women considering clinical testing for BRCA1/2 mutations. Genet Test 6:115–118PubMedCrossRef
27.
Zurück zum Zitat Tinley ST, Houfek J, Watson P et al (2004) Screening adherence in BRCA1/2 families is associated with primary physicians’ behavior. Am J Med Genet A 125A:5–11PubMedCrossRef Tinley ST, Houfek J, Watson P et al (2004) Screening adherence in BRCA1/2 families is associated with primary physicians’ behavior. Am J Med Genet A 125A:5–11PubMedCrossRef
28.
Zurück zum Zitat Uyei A, Peterson SK, Erlichman J et al (2006) Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer 107:2745–2751PubMedCrossRef Uyei A, Peterson SK, Erlichman J et al (2006) Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer 107:2745–2751PubMedCrossRef
29.
Zurück zum Zitat Litton JK, Westin SN, Ready K et al (2009) Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115:1598–1604PubMedCrossRef Litton JK, Westin SN, Ready K et al (2009) Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115:1598–1604PubMedCrossRef
30.
Zurück zum Zitat Morgan D, Sylvester H, Lucas FL et al (2010) Hereditary breast and ovarian cancer: referral source for genetic assessment and communication regarding assessment with nongenetic clinicians in the community setting. Genet Med 12:25–31PubMedCrossRef Morgan D, Sylvester H, Lucas FL et al (2010) Hereditary breast and ovarian cancer: referral source for genetic assessment and communication regarding assessment with nongenetic clinicians in the community setting. Genet Med 12:25–31PubMedCrossRef
31.
Zurück zum Zitat Cheung WY, Neville BA, Cameron DB et al (2009) Comparisons of patient and physician expectations for cancer survivorship care. J Clin Oncol 27:2489–2495PubMedCrossRef Cheung WY, Neville BA, Cameron DB et al (2009) Comparisons of patient and physician expectations for cancer survivorship care. J Clin Oncol 27:2489–2495PubMedCrossRef
32.
Zurück zum Zitat Hall MA, McEwen JE, Barton JC et al (2005) Concerns in a primary care population about genetic discrimination by insurers. Genet Med 7:311–316PubMedCrossRef Hall MA, McEwen JE, Barton JC et al (2005) Concerns in a primary care population about genetic discrimination by insurers. Genet Med 7:311–316PubMedCrossRef
33.
Zurück zum Zitat Rowley PT, Loader S (1996) Attitudes of obstetrician-gynecologists toward DNA testing for a genetic susceptibility to breast cancer. Obstet Gynecol 88:611–615PubMedCrossRef Rowley PT, Loader S (1996) Attitudes of obstetrician-gynecologists toward DNA testing for a genetic susceptibility to breast cancer. Obstet Gynecol 88:611–615PubMedCrossRef
34.
Zurück zum Zitat Barrison AF, Smith C, Oviedo J et al (2003) Colorectal cancer screening and familial risk: a survey of internal medicine residents’ knowledge and practice patterns. Am J Gastroenterol 98:1410–1416PubMedCrossRef Barrison AF, Smith C, Oviedo J et al (2003) Colorectal cancer screening and familial risk: a survey of internal medicine residents’ knowledge and practice patterns. Am J Gastroenterol 98:1410–1416PubMedCrossRef
35.
Zurück zum Zitat Blazer KR, Grant M, Sand SR et al (2004) Effects of a cancer genetics education programme on clinician knowledge and practice. J Med Genet 41:518–522PubMedCrossRef Blazer KR, Grant M, Sand SR et al (2004) Effects of a cancer genetics education programme on clinician knowledge and practice. J Med Genet 41:518–522PubMedCrossRef
36.
Zurück zum Zitat Schroy PC 3rd, Barrison AF, Ling BS et al (2002) Family history and colorectal cancer screening: a survey of physician knowledge and practice patterns. Am J Gastroenterol 97:1031–1036PubMedCrossRef Schroy PC 3rd, Barrison AF, Ling BS et al (2002) Family history and colorectal cancer screening: a survey of physician knowledge and practice patterns. Am J Gastroenterol 97:1031–1036PubMedCrossRef
37.
Zurück zum Zitat Offit K, Greene MH (2004) ASCO curriculum: cancer genetics and cancer predisposition testing, 2nd edn. ASCO Publishing, Alexandria, VA Offit K, Greene MH (2004) ASCO curriculum: cancer genetics and cancer predisposition testing, 2nd edn. ASCO Publishing, Alexandria, VA
Metadaten
Titel
Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care center
verfasst von
K. Ready
B. K. Arun
K. M. Schmeler
A. Uyei
J. K. Litton
K. H. Lu
C. C. Sun
S. K. Peterson
Publikationsdatum
01.12.2011
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 4/2011
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-011-9460-z

Weitere Artikel der Ausgabe 4/2011

Familial Cancer 4/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.